BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64:1923-1940. [PMID: 15329044 DOI: 10.2165/00003495-200464170-00011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Martell-Claros N, de la Cruz JJ. Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study. Clin Drug Investig 2011;31:427-34. [PMID: 21528940 DOI: 10.2165/11587400-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. Eur J Pharmacol. 2016;791:8-24. [PMID: 27568833 DOI: 10.1016/j.ejphar.2016.08.022] [Cited by in Crossref: 123] [Cited by in F6Publishing: 105] [Article Influence: 24.6] [Reference Citation Analysis]
3 Payeras AC, Sladek K, Lembo G, Alberici M. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. Clin Drug Investig 2007;27:623-32. [PMID: 17705571 DOI: 10.2165/00044011-200727090-00004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Correa ITS, da Costa-Silva TA, Tempone AG. Bioenergetics impairment of Trypanosoma cruzi by the antihypertensive manidipine: A drug repurposing strategy. Acta Trop 2021;214:105768. [PMID: 33245907 DOI: 10.1016/j.actatropica.2020.105768] [Reference Citation Analysis]
5 Hayden MR, Sowers JR. Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens 2008;2:239-66. [PMID: 20409906 DOI: 10.1016/j.jash.2007.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
6 Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs 2005;65 Suppl 2:11-9. [PMID: 16398058 DOI: 10.2165/00003495-200565002-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. [PMID: 16398060 DOI: 10.2165/00003495-200565002-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
8 Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS. Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. J Cardiovasc Pharmacol Ther. 2013;18:113-118. [PMID: 23113965 DOI: 10.1177/1074248412463611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Mercorelli B, Luganini A, Celegato M, Palù G, Gribaudo G, Loregian A. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein. Antiviral Research 2018;150:130-6. [DOI: 10.1016/j.antiviral.2017.12.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
10 Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Review of Cardiovascular Therapy 2014;5:147-59. [DOI: 10.1586/14779072.5.2.147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Wang S, Liu Y, Guo J, Wang P, Zhang L, Xiao G, Wang W. Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection. J Virol 2017;91:e01055-17. [PMID: 28814523 DOI: 10.1128/JVI.01055-17] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
12 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
13 Mishra AP, Bajpai A, Rai AK. 1,4-Dihydropyridine: A Dependable Heterocyclic Ring with the Promising and the Most Anticipable Therapeutic Effects. MRMC 2019;19:1219-54. [DOI: 10.2174/1389557519666190425184749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
14 Tocci G, Battistoni A, Passerini J, Musumeci MB, Francia P, Ferrucci A, Volpe M. Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther 2015;20:121-30. [PMID: 25398848 DOI: 10.1177/1074248414555403] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
15 Kim S, Yu YM, Kwon J, Yoo H, Jung SH, Lee E. Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review. Int J Environ Res Public Health 2019;16:E1333. [PMID: 31013922 DOI: 10.3390/ijerph16081333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 2005;65 Suppl 2:1-10. [PMID: 16398057 DOI: 10.2165/00003495-200565002-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
17 Stump CS, Hamilton MT, Sowers JR. Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 2006;81:796-806. [DOI: 10.4065/81.6.796] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]